Stem Cell Use in Liver Cirrhosis
Undifferentiated Bone Marrow
In all human trials involving the infusion of stem cells into a cirrhotic patient, the type of stem cell has been clearly identified and defined. A trial utilising unspecified BMSCs is recruiting with view to expand the data in this area.
In some of the earlier trials involving animal models, extracted bone marrow was re-infused back into the mice without any isolation of a particular stem cell type. In these trials, the mice were killed prior to the extraction of the BMSCs. Hepatic fibrosis was induced by administration of carbon tetrachloride (CCl4) in the mice that were to undergo the treatment. The results showed that up to 25 % of the liver had been repopulated 4 weeks after stem cell administration (Terai et al. 2003). All the trials showed an improvement in liver function and a reduction in liver fibrosis following the therapy (Ali and Masoud 2012; Zheng and Liang 2008; Iwamoto et al. 2013).